EUVIMEDDécouvrir EUVIMED
BeobachtungsstudieMultizentrische Studie

Contemporary neoadjuvant strategies for rectal cancer: The GRECCAR snapshot study

Antoine Cazelles, Quentin Denost, Benjamin Fernandez, Michel Rivoire, Hélène Meillat, Philippe Rouanet, Mehdi Karoui, Adeline Germain, Leon Maggiori, Alain Valverde, Nicolas Peru, Eddy Cotte and 20 more

Colorectal Disease · 2026

DOI: 10.1111/codi.70358 ↗

At a glance

Beobachtungsstudie in Colorectal Disease, 2026. Written by Antoine Cazelles and 31 co-authors. Institution: Department of Digestive and Oncological Surgery, Georges Pompidou University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, …. Major MEDLINE topics: Rectal Neoplasms, Neoadjuvant Therapy, Adenocarcinoma. 40 references.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Aim

Neoadjuvant treatment for rectal cancer has evolved markedly with the growing adoption of total neoadjuvant therapy ( TNT ), organ‐preservation strategies and selective omission of radiotherapy. Recent trials support risk‐based personalization, but its application in real‐world settings remains poorly documented. The aim was to describe current neoadjuvant treatment practices for mid‐low rectal cancer in French expert centres and identify tumour‐ and patient‐related factors influencing decisions.

Method

This observational study included patients with non‐metastatic rectal adenocarcinoma ≤10 cm from the anal verge, discussed in tumour boards (October 2022 to March 2023) across GRECCAR centres. Tumours were classified as early, intermediate‐risk or locally advanced rectal cancer (LARC). Neoadjuvant treatments were analysed according to tumour extension, location and age.

Results

Among 463 patients from 27 centres, the most frequent regimen was induction chemotherapy, mainly FOLFIRINOX, followed by long‐course chemoradiotherapy (CRT) (65%). This approach was used in 51%, 66% and 71% of patients in the early, intermediate‐risk and LARC groups, respectively ( p = 0.0060). TNT was more frequently administered for low‐ than mid‐rectal cancers, especially in LARC (86% vs. 71%, p = 0.016). In patients >75 years, CRT + consolidation chemotherapy and radiotherapy alone were proportionally more frequent. Among the early rectal cancers, those treated with induction chemotherapy + CRT had more advanced features than those treated with CRT alone (cT3: 80% vs. 43%, cN+: 62% vs. 10%, tumour size: 3.4 vs. 2.3 cm; all p < 0.001).

Conclusion

TNT with induction chemotherapy is the predominant neoadjuvant approach in French expert centres. Tumour classification, location and patient age significantly influence treatment choices, reflecting a shift towards personalized context‐specific care.

Subjects

MeSH terms (MEDLINE)

Rectal NeoplasmsNeoadjuvant TherapyAdenocarcinomaHumansMaleFemaleMiddle AgedAgedFranceAntineoplastic Combined Chemotherapy ProtocolsFluorouracilOxaliplatinInduction ChemotherapyLeucovorinIrinotecanAdultChemoradiotherapy, AdjuvantChemoradiotherapyAged, 80 and over

Author keywords

locoregional tumour extensionneoadjuvant treatmentobservational studypatient agerectal cancertotal neoadjuvant treatment

Substances

FluorouracilOxaliplatinLeucovorinIrinotecanfolfirinox

Authors and institutions

  • Department of Digestive and Oncological Surgery, Georges Pompidou University Hospital, Assistance Publique Hôpitaux de Paris, Paris Cité University, Paris, France.
  • Bordeaux Colorectal Institute, Clinique Tivoli-Ducos, Bordeaux, France.
  • Department of Digestive Surgery, Colorectal Unit, Haut-Lévêque Hospital, Bordeaux University Hospital, Pessac, France.
  • Department of Surgical Oncology, Centre Léon Bérard, Comprehensive Cancer Center, Lyon, France.
  • Department of Digestive Surgical Oncology, Institute Paoli-Calmettes, Marseille, France.
  • Department of Oncological Surgery, Val d'Aurelle Institut, Montpellier, France.

Cite

APA

Cazelles, A., Denost, Q., Fernandez, B., Rivoire, M., Meillat, H., Rouanet, P., Karoui, M., Germain, A., Maggiori, L., Valverde, A., Peru, N., Cotte, E., Buscail, E., Lefevre, J. H., Trilling, B., Faucheron, J. L., Sage, P. Y., Beyer-Berjot, L., Benoist, S., …, & French Research Group of Rectal Cancer Surgery (GRECCAR) (2026). Contemporary neoadjuvant strategies for rectal cancer: The GRECCAR snapshot study. Colorectal Disease. https://doi.org/10.1111/codi.70358

Vancouver

Cazelles A, Denost Q, Fernandez B, Rivoire M, Meillat H, Rouanet P, et al. Contemporary neoadjuvant strategies for rectal cancer: The GRECCAR snapshot study. Colorectal Disease. 2026. doi:10.1111/codi.70358

BibTeX
@article{Cazelles2026,
  author = {Cazelles, Antoine and Denost, Quentin and Fernandez, Benjamin and Rivoire, Michel and Meillat, Hélène and Rouanet, Philippe and Karoui, Mehdi and Germain, Adeline and Maggiori, Leon and Valverde, Alain and Peru, Nicolas and Cotte, Eddy and Buscail, Etienne and Lefevre, Jeremie H and Trilling, Bertrand and Faucheron, Jean Luc and Sage, Pierre Yves and Beyer-Berjot, Laura and Benoist, Stephane and Alves, Arnaud and Sabbagh, Charles and Tuech, Jean-Jacques and Coget, Julien and Marchal, Frédéric and Meurette, Guillaume and Mège, Diane and Djelil, Dahbia and Manfredelli, Simone and Venara, Aurélien and Ouaissi, Mehdi and Manceau, Gilles and French Research Group of Rectal Cancer Surgery (GRECCAR), French Research Group of Rectal Cancer Surgery (GRECCAR)},
  title = {Contemporary neoadjuvant strategies for rectal cancer: The GRECCAR snapshot study},
  journal = {Colorectal Disease},
  year = {2026},
  doi = {10.1111/codi.70358}
}
Start for free →